EurekaBio Secures Hundred-Million-Yuan Series B Financing to Advance CGT Upstream Technology Platform

VCBeat has learned that recently,Shenzhen Shenyan Biological Technology Co. LTD (hereinafter referred to as “Shenyan Bio”) announced the completion of its Series B financing, amounting to hundreds of millions of yuan. This round was led by S Capital, with participation from Jiufei Investment and Juke Investment. An existing shareholder, a well-known international industrial group, continued its investment, while Xinghan Capital served as the exclusive financial advisor.

Established in 2014, Shenzhen Shenyan Biological Technology Co., LTD provides comprehensive solutions for the cell and gene therapy (CGT) industry through the deep interdisciplinary integration of multi-disciplinary technologies with life sciences and technological innovation. The funds raised in this roundThe funds will be used for the research and development of an intelligent production equipment platform for cellular therapy, as well as for market expansion both domestically and internationally. Meanwhile, efforts will be further intensified to advance the R&D of large-scale viral vector production technologies., bringing richer upstream core technologies and products to the CGT industry, and further promoting cost reduction and efficiency improvement in the CGT sector.

Supported by policies, technology, and downstream markets, the CGT therapy industry is entering a “fast lane.”

From a global market perspective, according to Frost & Sullivan data, the global CGT market size is projected to reach $30.54 billion in 2025, with a compound annual growth rate (CAGR) of 71% from 2020 to 2025. China’s CGT market is expected to maintain rapid growth, with the overall market size reaching $2.59 billion in 2025 and a CAGR of 276% from 2020 to 2025.

The research, development, and regulatory approval of cell and gene therapy (CGT) products in China are increasingly on the rise. In 2021, two domestically developed cell therapy products received marketing approval in China. In early 2022, Legend Biotech’s BCMA-targeted cell therapy product obtained successive approvals in the United States and the European Union, marking the beginning of international expansion for Chinese cell therapies. In the field of gene therapy, Boya Biotherapeutics’ ET-01 became the first domestically developed gene-editing therapeutic product to receive approval for registrational clinical trials in early 2021. Over the past year, related products from companies such as Xinian, Neurophth, and Longxin Biopharmaceuticals have successively gained clinical trial approvals, signaling that China’s gene therapy industry has officially entered the clinical era.

As the cell and gene therapy (CGT) industry rapidly expands, scaling up upstream key technologies and products has become a core competitive factor. Shenzhen Shenyan Biological Technology Co., LTD aims to address unmet critical needs in the upstream segment by leveraging interdisciplinary integration and technological innovation across computer science, electronic engineering, nanomaterials, chemical engineering, and life sciences. The company is dedicated to overcoming a series of technical and process challenges in CGT, advancing automation, digitalization, and intelligence in biotechnology R&D, thereby helping the CGT industry reduce costs and improve efficiency.

Shenzhen Shenyan Biological Technology Co. LTD has currently laid out multiple business segments.Its upstream equipment R&D business segment features CellSep, a fully enclosed automated cell processing system, as one of its core products.^®PRO (abbreviated as CSP), applicable to the standardized production of various cell therapy products, has assisted leading enterprises in multiple cell therapy sectors (including CAR-T, TCR-T, CAR-NK, TIL, stem cell drugs, etc.) to complete IND submissions, Phase I and Phase II clinical trials.

Another core business segment of Shenzhen Shenyan Biological Technology Co. LTD——Biotechnology Development Segment: One of its core products is a lentiviral vector production system based on stable cell lines.This technology has overcome the technical bottlenecks in the large-scale production of lentiviral vectors, significantly improving production efficiency and product consistency while substantially reducing manufacturing costs, thereby driving innovation in viral vector production technologies.

Leveraging its diversified business segments and continuously launched innovative devices and technologies,Shenzhen Shenyan Biological Technology Co., LTD has significantly reduced process complexity and production costs across the industry by optimizing upstream supply chains, thereby enabling affordable cell and gene therapy (CGT) solutions for patients in China.

Mr. Ma Mo, Co-founder and CEO of Shenzhen Shenyan Biological Technology Co., LTD“We are delighted to have gained the recognition and support of both new and existing shareholders. This round of financing will further strengthen the service capabilities of our existing products, enabling us to deliver better products and services to our customers. Meanwhile, it will accelerate the R&D, innovation, and commercialization of our new products. Having identified the technical bottlenecks in large-scale viral vector production upstream of the cell and gene therapy (CGT) industry, as well as the demand for closed, automated equipment for cell preparation, we look forward to working closely with our investors. Together, we aim to provide technologically advanced, reliable, and cost-effective products and services to the CGT industry. By leveraging technological innovations to address process-related pain points and reduce production costs, we strive to help our customers make their CGT products accessible to more patients.”

Dr. Shi Lei, Partner at ST CapitalSteadfast Capital stated: “Steadfast Capital is committed to supporting platform enterprises with globally leading technologies and independent innovation capabilities. Cell and gene therapy (CGT) is a sector in which we maintain strong confidence and continue to increase our investments. Shenzhen Shenyan Biological Technology Co., LTD has earned recognition from leading domestic and international companies in the upstream CGT production space, leveraging its unique interdisciplinary advantages and deep expertise in the field. Steadfast Capital looks forward to working hand in hand with this globally minded team, alongside both new and existing investors. We believe that Shenzhen Shenyan Biological Technology Co., LTD will grow into a global leader in the upstream cell and gene therapy sector.”

Mr. Lin Hengcong, General Manager of Jiufei Capitalstated: “Shenyan Bio has been deeply engaged in the field of cell and gene therapy (CGT). Its lentiviral vector technology is at a globally leading level and has gradually gained recognition within the CGT industry. We are delighted to support such an outstanding team with leading technologies and products. We believe that, in time, Shenyan Bio will surely become a leading enterprise competing on the global stage and making significant contributions to the field of cell and gene therapy.”

Ms. Cao Ting, Partner at Juke Investmentstated: “Cell processing systems are key process equipment in the upstream segment of the cell and gene therapy industry. However, this field has long been monopolized by foreign companies. Shenyan Bio’s CellSep”^®“The product series has initially achieved market scale, securing orders from multiple CGT industry enterprises both domestically and internationally. We believe that Shenzhen Shenyan Biological Technology Co., LTD’s products offer greater advantages in terms of cost and localized service. From the perspectives of supply chain security and the development trends of the CGT industry, supporting such a company is highly meaningful. We look forward to Shenzhen Shenyan Biological Technology becoming a globally leading core equipment supplier and biotechnology service provider in the field of cell and gene therapy.”

Fidelity International’s venture capital arm, F-Prime Capital (known as Sida Capital in China), is a global investment firm backed by Fidelity Investments. With over $11 billion in assets under management globally, its investment teams are spread across China, India, Japan, Europe, and the United States. Leveraging its unique capital structure, F-Prime Capital flexibly deploys funds to support innovative companies in disrupting or leading their respective markets. Globally, the firm focuses on early- and growth-stage investments in the healthcare and technology sectors, having invested in more than 300 high-growth innovative enterprises.With over 25 years of venture capital experience in China, F-Prime Capital has invested in more than 150 companies in the healthcare and technological innovation fields, including Alibaba, WuXi AppTec, Innovent Biologics, Adagene, Boner Orthopedics, Aier Eye Hospital Group, Insilico Medicine, Westlake Biopharmaceuticals, Jiutian Biopharmaceuticals, and Semma Therapeutics.

Jiufei Capital is a professional private equity fund management company headquartered in Shenzhen. Established in June 2015, the firm currently manages seven RMB-denominated equity investment funds. Adhering to a philosophy of refined investment, Jiufei Capital focuses on equity investments in advanced manufacturing, healthcare, and major consumer sectors. To date, it has completed investments in nearly 20 projects, with several having successfully gone public or initiated IPO filing processes.

Juke Capital is a venture capital firm founded by Mr. Xu Gangwu, an early co-founder of Tencent, guided by the philosophy of long-term value investing. Since entering the venture capital industry in 2008, Juke Capital has established professional teams in Shenzhen, Beijing, Chengdu, Hong Kong, and Switzerland. To date, it has invested in over 40 companies, participated in eight domestic and international private equity funds, and reached a total investment scale of RMB 1.5 billion. In the healthcare sector, its portfolio spans key areas including biological products, cell therapy, advanced drug formulations, AI-driven drug discovery, and assisted reproductive technologies.